{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:53:27Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 19.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-02d3-7d42-8c11-46844379dd2f\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: laninamivir\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 78.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-02d0-7b12-848c-6f1e25b319d3\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: laninamivir\nRegistry id: vr.tr.laninamivir\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:27+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q6487096", "registryId": "vr.tr.laninamivir", "name": "laninamivir", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q6487096/", "model": { "registry_id": "vr.tr.laninamivir", "name": "laninamivir", "purpose": "Enable an AI agent to recognise laninamivir, assess the identity and fitness of a material or measurement attributed to it, and determine which research or handling actions its evidence supports.", "definition": "Laninamivir is a small-molecule antiviral that inhibits influenza A and B virus neuraminidase and is the active metabolite of the inhaled prodrug laninamivir octanoate.", "scope_statement": "This model owns laninamivir as the molecular substance registered as vr.tr.laninamivir in PHY / PHY.MAT, including its material state, analytical identity, neuraminidase inhibition and relationship to its octanoate prodrug.", "in_scope": [ "Molecular identity, stereochemistry and substance identifiers", "Laninamivir material composition, purity, physical form and stability", "Analytical discrimination of laninamivir from its octanoate prodrug and related compounds", "Influenza neuraminidase inhibition with assay and viral-variant context", "Formation and measurement of laninamivir following prodrug conversion", "Substance-specific handling evidence and permitted-use constraints" ], "out_of_scope": [ "Laninamivir octanoate and its hydrate as independently identified substances", "Finished inhalation products, excipients and delivery devices", "Patient diagnosis, prescribing and treatment selection", "Influenza viruses and disease progression beyond their relationship to measured activity", "Manufacturing process design and plant operation" ], "distinguishing_features": [ "Match the stereochemically specified structure associated with PubChem CID 502272; a name match alone does not establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Laninamivir)", "Check the molecular formula C13H22N4O7 against the octanoate ester's C21H36N4O8; the ester belongs to a related substance model. [Laninamivir](https://pubchem.ncbi.nlm.nih.gov/compound/Laninamivir), [laninamivir octanoate](https://pubchem.ncbi.nlm.nih.gov/compound/Laninamivir-octanoate)", "Distinguish the active inhibitor from its octanoate prodrug: pulmonary hydrolysis of the prodrug produces laninamivir. [Primary study](https://pubmed.ncbi.nlm.nih.gov/24682756/)", "Require a structure-discriminating analytical result when separating laninamivir from other neuraminidase inhibitors; antiviral activity alone cannot identify the substance." ], "characteristics": [ { "name": "Stereochemical identity", "kind": "category", "unit_or_values": "Validated isomeric structure, InChI or equivalent stereochemical representation", "why_it_matters": "Prevents structurally related inhibitors or stereoisomers from being accepted solely on a shared name or formula." }, { "name": "Substance identifier mapping", "kind": "relation", "unit_or_values": "Registry id vr.tr.laninamivir; verified external identifiers with source and retrieval date", "why_it_matters": "Keeps active-substance records separate from prodrug, hydrate and product records." }, { "name": "Laninamivir assay content", "kind": "measurement", "unit_or_values": "% mass fraction or amount fraction; method and as-is or corrected basis required", "why_it_matters": "Determines the amount of laninamivir present without equating chromatographic peak area with absolute content." }, { "name": "Related-substance profile", "kind": "measurement", "unit_or_values": "Individual impurity concentrations or percentages with identification confidence and detection limits", "why_it_matters": "Reveals residual prodrug, degradation products or other components that could distort use or interpretation." }, { "name": "Physical and ionic form", "kind": "state", "unit_or_values": "Solid or solution; crystalline or amorphous where established; counterions, water, solvent, pH and temperature", "why_it_matters": "Connects reported properties and concentration calculations to the actual material examined." }, { "name": "Solubility under specified conditions", "kind": "measurement", "unit_or_values": "mg/mL or mol/L, with solvent, pH, temperature and equilibration method", "why_it_matters": "Supports preparation of suitable assay solutions and interpretation of precipitation or exposure limitations." }, { "name": "Neuraminidase inhibition", "kind": "measurement", "unit_or_values": "IC50 or Ki in nM or µM with enzyme variant, substrate and assay conditions", "why_it_matters": "Makes potency comparable only where the target and experimental conditions support comparison." }, { "name": "Prodrug conversion relationship", "kind": "relation", "unit_or_values": "Laninamivir octanoate to laninamivir; matrix, conversion conditions and evidence", "why_it_matters": "Separates formation of the active substance from its subsequent distribution or elimination." }, { "name": "Measured biological concentration", "kind": "measurement", "unit_or_values": "ng/mL, ng/g or nmol/L with matrix, sampling time and analyte-specific method", "why_it_matters": "Prevents prodrug concentrations, active-substance concentrations and administered dose from being treated as interchangeable." }, { "name": "Handling and use status", "kind": "category", "unit_or_values": "Documented hazard assessment, material grade and authorised use, each with jurisdiction and date where applicable", "why_it_matters": "Supports decisions about a particular material without inheriting a finished medicine's status." } ], "affordances": [ "Resolve a name or identifier to laninamivir and flag links that actually describe its prodrug or a formulated product.", "Assess whether a material lot has sufficient identity, content and impurity evidence for a specified research use.", "Calculate laninamivir quantities using the documented content and material-form basis.", "Compare inhibition measurements after checking target variants and assay compatibility.", "Trace laninamivir measurements to prodrug conversion, sample handling and analytical selectivity.", "Select storage or handling actions supported by evidence for the actual material." ], "agent_conduct": { "may": [ "Identify laninamivir and its inhaled prodrug by name and identifiers, citing sources.", "Report where it is authorized and for what, from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Advise a particular person to take it or how much, in place of a prescriber.", "Confuse the active metabolite with the inhaled prodrug in records or advice.", "Supply it outside lawful pharmaceutical channels.", "Overstate its effect against influenza or present it as a vaccine substitute." ], "requires_human": [ "Any decision to treat or give prophylaxis to a patient.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "During influenza outbreaks, antiviral supply and honest claims affect who gets protected.", "Resistance can spread if antivirals are used carelessly." ], "affected_parties": [ "Patients with influenza", "Prescribers and pharmacists", "Public health services" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Clinical packs carry the prodrug name and an inhaler device rather than the metabolite." ], "failure_modes_and_hazards": [ "Inhaled use can trigger bronchospasm in people with airway disease.", "Mixing up prodrug and metabolite data leads to wrong conclusions in research or dosing.", "Substandard or falsified lots give no protection during an outbreak." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "This compound is encountered in influenza antiviral research and in studies of the active metabolite produced from its inhaled prodrug.", "Laboratories use it in investigations of neuraminidase inhibition, antiviral susceptibility and drug metabolism." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q6487096: laninamivir", "url": "https://www.wikidata.org/wiki/Q6487096", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Laninamivir", "url": "https://en.wikipedia.org/wiki/Laninamivir", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "active-substance-identity", "name": "Active-substance identity", "description": "Establish which chemical entity a laninamivir record represents.", "rationale": "The active inhibitor and its octanoate prodrug are closely linked in the literature but cannot share a substance identity.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Anchor the entry to a stereochemically resolved molecular identity.", "findings": [ { "id": "identity-concordance", "name": "Identity concordance", "description": "Require agreement between the named substance, structure and external identifier records.", "questions": [ { "text": "Which stereochemically explicit structure defines laninamivir for this registry entry?", "kind": "definition", "id": "identity-concordance-q01" }, { "text": "Which read authority records establish its CAS number, PubChem CID and other identifiers without mapping them to the octanoate ester?", "kind": "provenance", "id": "identity-concordance-q02" } ] } ] }, { "id": "prodrug-and-product-boundaries", "name": "Prodrug and product boundaries", "description": "Represent related substances and products through explicit relationships.", "findings": [ { "id": "active-versus-administered-entity", "name": "Active versus administered entity", "description": "Laninamivir octanoate is an ester prodrug that undergoes hydrolytic bioactivation to laninamivir. [Primary study](https://pubmed.ncbi.nlm.nih.gov/24682756/)", "questions": [ { "text": "Does each cited experiment administer or test laninamivir itself, laninamivir octanoate, or a formulation containing the prodrug?", "kind": "boundary", "id": "active-versus-administered-entity-q01" }, { "text": "Which related registry or publication record should own the prodrug or formulation while this entry records the relationship?", "kind": "action", "id": "active-versus-administered-entity-q02" } ] } ] } ] }, { "id": "material-quality-and-state", "name": "Material quality and state", "description": "Describe the laninamivir material actually available for examination or use.", "rationale": "Molecular identity does not establish usable content, solution behaviour or stability of a particular lot.", "layers": [ { "id": "content-and-related-substances", "name": "Content and related substances", "description": "Separate laninamivir content from impurities, water and solvents.", "findings": [ { "id": "lot-composition", "name": "Lot composition", "description": "Record the basis and selectivity of the lot assay, including any residual octanoate prodrug.", "questions": [ { "text": "What laninamivir content was measured, by which method, and on an as-is, dry or other corrected basis?", "kind": "measurement", "id": "lot-composition-q01" }, { "text": "Which related substances, residual solvents and water contributions were measured rather than inferred from a purity label?", "kind": "measurement", "id": "lot-composition-q02" } ] } ] }, { "id": "physical-state-and-stability", "name": "Physical state and stability", "description": "Bind physical properties and storage claims to the tested form and conditions.", "findings": [ { "id": "condition-dependent-usability", "name": "Condition-dependent usability", "description": "Require direct evidence for dissolution, phase behaviour and retention of laninamivir content during storage.", "questions": [ { "text": "What physical form, solvent, pH and temperature accompany the measured solubility and any thermal-transition result?", "kind": "measurement", "id": "condition-dependent-usability-q01" }, { "text": "Which storage, solution-holding and freeze-thaw limits are supported by stability-indicating measurements for this material?", "kind": "action", "id": "condition-dependent-usability-q02" } ] } ] } ] }, { "id": "neuraminidase-inhibition", "name": "Neuraminidase inhibition", "description": "Organise evidence about laninamivir's target activity and antiviral effects.", "rationale": "A neuraminidase-inhibitor label alone cannot establish potency against a particular viral variant or predict a cellular result.", "layers": [ { "id": "target-and-assay", "name": "Target and assay", "description": "Identify the enzyme and experimental system underlying each inhibition measurement.", "findings": [ { "id": "interpretable-potency", "name": "Interpretable potency", "description": "Treat potency as a result of a specified laninamivir preparation and assay rather than a universal substance constant.", "questions": [ { "text": "Which influenza neuraminidase type, subtype, strain and sequence variant were tested?", "kind": "definition", "id": "interpretable-potency-q01" }, { "text": "What IC50 or Ki was measured, with what substrate concentration, incubation conditions, controls and uncertainty?", "kind": "measurement", "id": "interpretable-potency-q02" } ] } ] }, { "id": "susceptibility-and-translation", "name": "Susceptibility and translation", "description": "Separate biochemical susceptibility, cellular antiviral effects and clinical inference.", "findings": [ { "id": "variant-and-system-dependence", "name": "Variant and system dependence", "description": "Record reduced-susceptibility evidence against its comparator and avoid transferring enzyme results directly to treatment outcomes.", "questions": [ { "text": "Which tested variants change laninamivir susceptibility, and what fold change relative to which reference supports that assessment?", "kind": "measurement", "id": "variant-and-system-dependence-q01" }, { "text": "Which cell-based antiviral and cytotoxicity results support the enzyme finding, and where does inference to clinical benefit remain unsupported?", "kind": "boundary", "id": "variant-and-system-dependence-q02" } ] } ] } ] }, { "id": "bioactivation-and-analyte-tracking", "name": "Bioactivation and analyte tracking", "description": "Track formation and measurement of laninamivir in biological systems.", "rationale": "Prodrug conversion and active-substance exposure must be distinguished to interpret concentration and duration claims.", "layers": [ { "id": "formation-from-octanoate", "name": "Formation from octanoate", "description": "Connect laninamivir formation to experimentally established hydrolysis conditions.", "findings": [ { "id": "conversion-evidence", "name": "Conversion evidence", "description": "Record the species, tissue and experimental evidence supporting conversion from the octanoate ester.", "questions": [ { "text": "Which enzymes or tissue preparations were directly shown to convert laninamivir octanoate to laninamivir?", "kind": "provenance", "id": "conversion-evidence-q01" }, { "text": "What conversion rate or fraction was measured under which substrate concentration and incubation conditions?", "kind": "measurement", "id": "conversion-evidence-q02" } ] } ] }, { "id": "selective-biological-measurement", "name": "Selective biological measurement", "description": "Make exposure observations traceable to the correct analyte and sampling context.", "findings": [ { "id": "analyte-specific-exposure", "name": "Analyte-specific exposure", "description": "Require selective measurement and control of sample-processing conversion before interpreting laninamivir concentrations.", "questions": [ { "text": "Does the validated assay distinguish laninamivir from its prodrug and quantify recovery, matrix effects and the lower limit of quantification?", "kind": "measurement", "id": "analyte-specific-exposure-q01" }, { "text": "How were collection and processing controlled to detect or prevent additional prodrug hydrolysis after sampling?", "kind": "provenance", "id": "analyte-specific-exposure-q02" }, { "text": "Does the reported persistence refer to laninamivir in a specified compartment, prodrug retention, or a pharmacodynamic effect?", "kind": "boundary", "id": "analyte-specific-exposure-q03" } ] } ] } ] }, { "id": "handling-and-use-evidence", "name": "Handling and use evidence", "description": "Determine which actions are supported for a particular laninamivir material.", "rationale": "A pharmacologically active metabolite does not automatically inherit the handling classification or authorisation of a medicine containing its prodrug.", "layers": [ { "id": "substance-specific-hazards", "name": "Substance-specific hazards", "description": "Attach handling evidence to laninamivir and the actual preparation.", "findings": [ { "id": "hazard-evidence-applicability", "name": "Hazard evidence applicability", "description": "Distinguish a documented hazard assessment from absent data or an assessment for another substance.", "questions": [ { "text": "Which current safety data sheet or primary assessment explicitly covers this laninamivir form and concentration?", "kind": "provenance", "id": "hazard-evidence-applicability-q01" }, { "text": "What handling, spill and disposal actions does that evidence support, and are any exposure limits actually established?", "kind": "action", "id": "hazard-evidence-applicability-q02" } ] } ] }, { "id": "grade-and-authorisation", "name": "Grade and authorisation", "description": "Evaluate intended use against material qualification and jurisdiction-specific evidence.", "findings": [ { "id": "use-eligibility", "name": "Use eligibility", "description": "Keep research-material qualification, reference-standard status and medicinal-product authorisation separate.", "questions": [ { "text": "What documentation qualifies this lot as a research reagent, analytical reference standard or another stated grade?", "kind": "provenance", "id": "use-eligibility-q01" }, { "text": "Does a cited regulatory decision cover laninamivir itself or a product containing laninamivir octanoate, and in which jurisdiction and period?", "kind": "boundary", "id": "use-eligibility-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is a recall-based description; no sources were consulted.", "Verify exact registry identifiers, stereochemical specification and physical properties for the active molecule separately from its prodrug and any hydrate.", "Check current jurisdiction-specific approvals and product safety information before adding regulatory or clinical details." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "laninamivir", "note": "Names the active molecule; laninamivir octanoate is its chemically distinct prodrug." }, { "scheme": "Development code", "value_or_pattern": "R-125489", "note": "Development identifier for laninamivir." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Provides the neuraminidase-inhibiting activity following administration and conversion of laninamivir octanoate.", "Used in research on influenza neuraminidase inhibition and antiviral susceptibility." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Changes in viral neuraminidase can reduce susceptibility; activity should not be assumed identical across influenza strains.", "Confusing laninamivir with laninamivir octanoate can cause errors in chemical identity, molecular mass, formulation descriptions and interpretation of experimental results." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Laninamivir octanoate has been used clinically in Japan; that history should not be treated as evidence of approval of laninamivir itself or approval in other jurisdictions." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "laninamivir octanoate", "difference": "An ester prodrug converted to laninamivir, rather than the active molecule itself." }, { "name": "zanamivir", "difference": "A related neuraminidase inhibitor; laninamivir is its 7-O-methyl derivative." }, { "name": "oseltamivir", "difference": "A structurally different antiviral prodrug whose active metabolite is oseltamivir carboxylate." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of laninamivir this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records reconcile laninamivir's CAS, EC and regulatory identifiers while excluding identifiers for its octanoate ester and hydrate?", "Which physical forms have experimentally established solubility, thermal behaviour and storage stability, and is decomposition more relevant than a boiling point?", "What validated impurity limits and assay criteria qualify laninamivir lots for specific research or reference-standard uses?", "Which current primary studies establish variant-specific susceptibility and the limits of translating enzyme inhibition into cellular or clinical effects?", "What substance-specific hazard classifications, occupational exposure limits and jurisdictional use statuses are documented for laninamivir itself?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 27 } }